The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.
Nat Commun
; 13(1): 1790, 2022 04 04.
Article
in En
| MEDLINE
| ID: mdl-35379805
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
CD28 Antigens
/
Neoplasms
Limits:
Animals
/
Humans
Language:
En
Journal:
Nat Commun
Journal subject:
BIOLOGIA
/
CIENCIA
Year:
2022
Type:
Article
Affiliation country:
United States